Atrial Fibrillation, Ventricular Arrhythmia, and Left Ventricular Remodeling in the ICU – First Results of the Single- Center RHYTHM-ACC Registry

Open access

Abstract

The aim of this study was to investigate the association between left ventricular remodeling, atrial fibrillation (AF), and the severity of ventricular tachycardia (VT) in patients with ventricular rhythm disturbances admitted in a level 3 facility of acute cardiac care. Material and Methods: The RHYTHM-ACC registry was a single-center observational study, including 150 consecutive patients with sustained or non-sustained ventricular tachycardia (sVT and nsVT, respectively) admitted in an intensive cardiac care unit (ICCU), separated in: group 1 - 29 patients (21.01%) with dilated cardiomyopathy (DCM), and group 2 - 109 patients (78.99%) with normal ventricular performance. We investigated the difference between clinical characteristics of patients with sVT versus those with nsVT in each study group, and the association between AF and different forms of ventricular arrhythmia in 38 (25.33%) patients with AF and 112 (74.66%) patients in sinus rhythm. Results: There were no significant differences between the study groups with respect to type of ventricular arrhythmia: sVT (46.87% vs. 36.44%, p = 0.2), nsVT (43.75% vs. 55.93%, p = 0.2), or ventricular fibrillation (VF) (9.37% vs. 7.62%, p = 0.7). However, patients with DCM presented a significantly higher incidence of AF (43.75% vs. 20.33%, p = 0.01) and bundle branch block (37.5% vs. 11.86%, p = 0.0007). VF occurred more frequently in patients with AF compared to those in sinus rhythm (18.42% vs. 4.46%, p = 0.006). Multivariate analysis identified the co-existence of AF (OR = 4.8, p = 0.01) and the presence of a bundle branch block (BBB) (OR = 3.9, p = 0.03) as the most powerful predictors for the degeneration of VT into VF in patients admitted with sVT or nsVT in an ICCU unit. Conclusions: In patients with any type of VT admitted in an ICCU, the presence of ventricular remodeling is associated with a higher incidence of AF and conduction abnormalities, but not with a more severe pattern of ventricular arrhythmia. At the same time, AF and BBB seem to represent the most powerful predictors for degeneration of VT into VF, independent of the type of VT.

1. Azevedo PS, Polegato BF, Minicucci MF, Paiva SA, Zornoff LA. Cardiac Remodeling: Concepts. Clinical Impact. Pathophysiological Mechanisms and Pharmacologic Treatment. Arq Bras Cardiol. 2016;106:62-69. doi:

2. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35:569-582.

3. Anand IS, Florea VG, Solomon SD, Konstam MA, Udelson JE. Noninvasive assessment of left ventricular remodeling: concepts, techniques, and implications for clinical trials. J Card Fail. 2002;8:S452-64. doi:

4. Liu L, Eisen HJ. Epidemiology of heart failure and scope of the problem. Cardiol Clin. 2014;32:1-8,vii. doi:

5. Pimentel M, Zimerman LI, Rohde LE. Stratification of the risk of sudden death in nonischemic heart failure. Arq Bras Cardiol. 2014;103:348-357. doi:

6. Braunwald E. Heart failure. JACC Heart Fail. 2013;1:1-20. doi:

7. Suthahar N, Meijers WC, Silljé HHW, de Boer RA. From Inflammation to Fibrosis - Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities. Curr Heart Fail Rep. 2017;14:235-250. doi:

8. Yndestad A, Damås JK, Oie E, Ueland T, Gullestad L, Aukrust P. Systemic inflammation in heart failure-the whys and wherefores. Heart Fail Rev. 2006;11:83-92. doi:

9. Heymans S, Hirsch E, Anker SD, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2009;11:119-129. doi:

10. Dick SA, Epelman S. Chronic heart failure and inflammation: what do we really know? Circ Res. 2016;119:159-176. doi:

11. Grieve DJ, Shah AM. Oxidative stress in heart failure: More than just damage. Eur Heart J. 2003;24:2161-2163. doi:

12. de Jong S, van Veen TA, de Bakker JM, Vos MA, van Rijen HV. Biomarkers of myocardial fibrosis. J Cardiovasc Pharmacol. 2011;57:522-535. doi:

13. Kotecha D, Piccini JP. Atrial fibrillation in heart failure: what should we do? Eur Heart J. 2015;36:3250-3257. doi:

14. Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation. 2009;119:2516-2525. doi:

15. Lee Park K, Anter E. Atrial Fibrillation and Heart Failure: A Review of the Intersection of Two Cardiac Epidemics. J Atr Fibrillation. 2013;6:751. doi:

16. Kalifa J, Jalife J, Zaitsev AV, et al. Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. Circulation. 2003;108:668-671. doi:

17. Lalani GG, Schricker A, Gibson M, Rostamian A, Krummen DE, Narayan SM. Atrial conduction slows immediately before the onset of human atrial fibrillation: a bi-atrial contact mapping study of transitions to atrial fibrillation. J Am Coll Cardiol. 2012;59:595-606. doi:

18. Mills RW, Narayan SM, McCulloch AD. Mechanisms of conduction slowing during myocardial stretch by ventricular volume loading in the rabbit. Am J Physiol Heart Circ Physiol. 2008;295:H1270-H1278. doi:

19. Stiles MK, John B, Wong CX, et al. Paroxysmal lone atrial fibrillation is associated with an abnormal atrial substrate: characterizing the ‘second factor’. J Am Coll Cardiol. 2009;53:1182-1191. doi:

20. Healey JS, Israel CW, Connolly SJ, et al. Relevance of electrical remodeling in human atrial fibrillation: results of the asymptomatic atrial fibrillation and stroke evaluation in pacemaker patients and the atrial fibrillation reduction atrial pacing trial mechanisms of atrial fibrillation study. Circ Arrhythm Electrophysiol. 2012;5:626-631. doi:

21. Kareti KR, Chiong JR, Hsu SS, Miller AB. Congestive heart failure and atrial fibrillation: rhythm versus rate control. J Card Fail. 2005;11:164-172. https://doi.org/10.1016/j.cardfail.2004.09.011.

22. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol. 2003;91:2D-8D.

23. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7:79-108. doi:

24. Pedersen CT, Kay GN, Kalman J, et al. ESC Scientific Document Group; EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. EP Europace. 2014;16:1257-1283. doi:

25. Katritsis DG, Camm AJ. Nonsustained ventricular tachycardia: where do we stand? Eur Heart J. 2004;15:1093-1099. doi:

26. Hadid C. Sustained ventricular tachycardia in structural heart disease. Cardiol J. 2015;22:12-24. doi:

27. Katritsis DG, Zareba W, Camm AJ. Nonsustained Ventricular Tachycardia. J Am Coll Cardiol. 2012;60:1993-2004. doi:

28. Myerburg RJ, Junttila MJ. Sudden cardiac death caused by coronary heart disease. Circulation. 2012;125:1043-1052. doi:

29. Benito B, Josephson ME. Ventricular tachycardia in coronary artery disease. Rev Esp Cardiol (Engl Ed). 2012;65:939-955. doi:

30. Weintraub RG, Semsarian C, Macdonald P. Dilated cardiomyopathy. Lancet. 2017;390:400-414. doi:

31. Merlo M, Cannatà A, Gobbo M, Stolfo D, Elliott PM, Sinagra G. Evolving concepts in dilated cardiomyopathy. Eur J Heart Fail. 2018;20:228-239. doi:

32. Mazur A, Kusniec J, Strasberg B. Bundle branch reentrant ventricular tachycardia. Indian Pacing Electrophysiol J. 2005;5:86-95.

33. Hodkinson EC, Aston K, Walsh SJ. Left bundle branch block morphology ventricular tachycardia in a marathon runner. Ulster Med J. 2012;81:130-133.

34. Gorenek B, Cengiz O, Kudaiberdieva G, et al. Mode of onset of polymorphic ventricular tachycardia in acute myocardial infarction. Can J Cardiol. 2010;26:e254-257.

35. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119-177. https://doi.org/10.1093/eurheartj/ehx393.

36. Blomstrom-Lundqvist C, Mazzanti A, Blom N, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Eur Heart J. 2015;36:2793-2867. doi:

37. Ellis ER, Josephson ME. What About Tachycardia-induced Cardiomyopathy? Arrhythm Electrophysiol Rev. 2013;2:82-90. doi:

38. Elliot P. Defining Tachycardia-Induced Cardiomyopathy. J Am Coll Cardiol. 2017;69:2173-2174. doi:

39. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological Mechanisms of Atrial Fibrillation: A Translational Appraisal. Physiol Rev. 2011;91:265-325. doi:

40. Ulus T, Kudaiberdieva G, Gorenek B. The onset mechanisms of ventricular tachycardia. Int J Cardiol. 2013;167:619-623. doi:

41. López Gil M, Arribas F, Cosío FG. Ventricular fibrillation induced by rapid atrial rates in patients with hypertrophic cardiomyopathy. Europace. 2000;2:327-332. https://doi.org/10.1053/eupc.2000.0117.

42. Link MS, Bockstall K, Weinstock J, et al. Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy and Defibrillators: Triggers, Treatment, and Implications. J Cardiovasc Electrophysiol. 2017;28:531-537. doi:

43. Espinoza CA, Mehra S, DeAntonio H. Double Trouble: Concurrent Atrial Fibrillation and Ventricular Tachycardia. Rev Esp Cardiol (Engl Ed). 2016;69:779-780. doi:

44. Osman F, Ward R, Morley-Davies A. Simultaneous spontaneous onset of ventricular tachycardia and termination of atrial fibrillation. Europace. 2008;10:171-172. doi:

45. Boriani G, Rapezzi C, Biffi M, Branzi A, Spirito P. Atrial fibrillation precipitating sustained ventricular tachycardia in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol.2002;13:954.

Journal Information

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 42 42 11
PDF Downloads 26 26 10